Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine
Information source: Federal University of São Paulo
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Myofascial Pain Syndromes
Intervention: bupivacaine and acupuncture (Drug)
Sponsored by: Federal University of São Paulo
Official(s) and/or principal investigator(s):
Miriam CB Gazi, MD, Principal Investigator, Affiliation: Federal University of Sao Paulo
CONTEXT AND OBJECTIVE: Myofascial syndrome is the most frequent condition of chronic pain.
The objective of the present study was to compare the analgesic action of acupuncture and
trigger point injection combined with cyclobenzaprine and dipyrone.
DESIGN AND SETTING: A randomized study was performed at the Pain Clinic. METHODS: Thirty
patients were divided into two groups: G1 received trigger point injection of 0. 25%
bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8
h. G2 was submitted to classical and trigger point acupuncture twice a week. The patients
were asked to continue physical exercise. The following parameters were evaluated: pain
intensity rated on a numerical and verbal scale, quality of life before and four weeks after
treatment, and quality of analgesia.
Official title: Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine on Pain Relief of Patients With Myofascial Pain: Randomized Clinical Study
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Pain relief
Secondary outcome: compare the analgesic action of acupuncture and trigger point injection combined with cyclobenzaprine and dipyrone
Among the 39 patients selected, nine (3 in group 1 and 6 in group 2) were excluded from the
study because they did not attend the visits scheduled for the procedures and assessment or
because they did not respond to the questionnaires.
Minimum age: 18 Years.
Maximum age: 65 Years.
Inclusion Criteria:- patients of both genders
- chronic myofascial syndrome (duration of more than three months),
- ranging in age from 18 to 65 year,
- pain intensity score of 3 or higher (rated on a numerical scale ranging from 0 to 10)
- patients with disc herniation,
- vertebral collapse,
- temporomandibular joint dysfunction,
- infection, -
- coagulopathy, -
- psychiatric disease,
- cognitive disorders.
- Patients who had used any type of analgesic or muscle relaxant agent 15 days before
the study and those taking anticoagulants
Locations and Contacts
Pain Setor of Federal University of Sao Paulo, Sao Paulo, SP, Brazil
Starting date: June 2004
Ending date: November 2006
Last updated: March 12, 2008